Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study

Απλή σελίδα τεκμηρίου
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorBeer, M.en
dc.contributor.authorMakrantonakis, P.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorPantelakos, P.en
dc.contributor.authorTsavaris, N.en
dc.contributor.authorKarpasitis, N.en
dc.contributor.authorKosmidis, P.en
dc.date.accessioned2015-11-24T19:04:58Z
dc.date.available2015-11-24T19:04:58Z
dc.identifier.issn0284-186X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20123
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnorexia/*drug therapy/etiologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMegestrol/adverse effects/*analogs & derivatives/therapeutic useen
dc.subjectMegestrol Acetateen
dc.subjectMiddle Ageden
dc.subjectNeoplasms/*complications/psychologyen
dc.subjectPilot Projectsen
dc.subjectQuality of Lifeen
dc.subjectWeight Loss/*drug effectsen
dc.titleMegestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) studyen
heal.abstractFifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10%, received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. Of the 41 patients treated during 4 weeks or longer, 38 experienced weight gain. Monthly subjective evaluation of six parameters using a linear analog self-assessment (LASA) form showed a significant improvement in the patient's rating of appetite, mood, nausea and vomiting, and quality of life; the tumor was progressive in 21, stable in 11 and it regressed in only 9 of these patients. No toxicity was observed; one case of death due to a congestive heart failure remains unexplained. MA at the dose used is a powerful appetite stimulant; it contributes to weight increase and might improve the subjective appreciation of quality of life. MA at lower doses should be compared in a prospective trial to the dose used in this study.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8466763-
heal.identifier.secondaryhttp://informahealthcare.com/doi/pdfplus/10.3109/02841869309083883-
heal.journalNameActa Oncolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1993-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ